Close this search box.

Keytruda still growing


Opdivo started stronger, but has long since plateaued. Their sales differential was over $4 billion last quarter.

By Meredith Durkin Wolfe, Director of Research

April 26, 2024 11:37 PM UTC

Sales of Keytruda pembrolizumab grew to $6.9 billion in 1Q24, with Merck and Co. Inc. (NYSE:MRK) reporting 5% growth from the prior quarter and 20% from 1Q23.

Sales of fellow anti-PD-1 mab Opdivo nivolumab reported by Bristol Myers Squibb Co. (NYSE:BMY) dipped in 1Q24, to $2.1 billion. BMS reported 4Q23 sales of $2.4 billion, and 1Q23 sales of $2.2 billion. Worldwide 1Q24 sales are estimated to be $2.3 billion including Japanese revenues reported by Ono Pharmaceutical Co. Ltd (Tokyo:4528), which guided to about ¥35 billion ($231.2 million) but will not report earnings until May 9. Ono’s guidance also represented a drop; sales in 4Q23 were ¥39.9 billion ($282.9 million)…